# Chemical Science

## EDGE ARTICLE

CrossMark
click for updates

# Catalytic radical reduction in aqueous solution *via* oxidation of biologically-relevant alcohols†

Yamin Htet[a] and Andrew G. Tennyson*[abc]

Metalloenzymes that normally perform catalytic antioxidant or radical-degrading functions, as well as small-molecule complexes that mimic them, can also exert pro-oxidant or radical-forming effects depending on the identity of the terminal reductant. Because nitroxyl radicals function as redox active cocatalysts in the aerobic oxidation of alcohols, we hypothesized that catalytic radical reduction could be achieved *via* the oxidation of biologically-relevant alcohols. Herein we report an organoruthenium complex (**Ru1**) that catalyzed reduction of 2,2′-azino-bis(3-ethylbenzo-thiazoline-6-sulfonate) radical monoanion (ABTS$^{\bullet-}$) to ABTS$^{2-}$ in phosphate buffered saline (pH 7.4) using MeOH, EtOH, i-PrOH, serine, threonine, glucose, arabinose, methyl lactate or dimethyl malate as the terminal reductant. Replacing either the C–H or O–H groups of a –CHOH– moiety resulted in the loss of ABTS$^{\bullet-}$ reducing ability. Moreover, in conjunction with an alcohol terminal reductant, **Ru1** was able to inhibit the oxidation of ABTS$^{2-}$ by H$_2$O$_2$ and horseradish peroxidase, even after multiple successive challenges with excess H$_2$O$_2$ or ABTS$^{\bullet-}$. Collectively, these results demonstrate that **Ru1** inhibits the oxidative formation of and catalyzes the reduction of radicals in aqueous solution *via* oxidation of biologically-relevant alcohols.

## Introduction

Reactive oxygen species (ROS) such as superoxide (O$_2^-$) and hydrogen peroxide (H$_2$O$_2$) can alter the structures and functions of biomolecules[1,2] *via* DNA base lesion formation,[3] transition metal ion release from proteins,[4] and membrane phospholipid chain degradation.[5] Antioxidants can prevent or attenuate this damage by reacting with ROS to yield less oxidizing, more stable radical or non-radical products. Superoxide dismutase (SOD) and catalase, for example, are metalloenzymes that protect cells by catalyzing the disproportionation of O$_2^-$ and H$_2$O$_2$, respectively.[6] Synthetic Mn–salen and Mn–porphyrin complexes have demonstrated both SOD and catalase activity,[7] and some have entered phase 1 clinical trials as therapeutics for neurodegenerative and pulmonary diseases.[8]

Recent studies have shown that these classes of synthetic Mn complexes can also exert pro-oxidant effects at low ROS concentrations,[9,10] dichotomous behavior that is consistent with the enzymes they mimic. Catalase converts 2H$_2$O$_2$ into O$_2$ + 2H$_2$O (Scheme 1-i),[11] wherein the first equivalent of H$_2$O$_2$ is reduced to H$_2$O and generates an Fe(IV)=O$^{\bullet+}$ intermediate,

which then oxidizes the second equivalent of H$_2$O$_2$ to O$_2$ and releases H$_2$O.[12] At low H$_2$O$_2$ concentrations, this Fe(IV)=O$^{\bullet+}$ intermediate can abstract H$^{\bullet}$ from other molecules (*i.e.*, A–H) and thus exhibit peroxidase-like reactivity (Scheme 1-ii).[13] Conversely, peroxidase can exhibit catalase-like reactivity at low A–H/high H$_2$O$_2$ concentrations.[14] Because the Mn–salen and Mn–porphyrin complexes proceed through high-valent Mn oxo/hydroxo intermediates[15–18] with oxidizing power comparable to Fe(IV)=O$^{\bullet+}$, their reactivity will mimic catalase or peroxidase based on the availability of H$_2$O$_2$. Therefore, the function of catalase and its biomimetic Mn complexes as either



**Scheme 1** Catalase normally catalyzes the disproportionation of 2H$_2$O$_2$ → O$_2$ + 2H$_2$O (i), but at low H$_2$O$_2$ concentrations it can abstract H$^{\bullet}$ from other molecules (A–H) and produce radicals (A$^{\bullet}$) in a manner similar to peroxidase (ii). Copper or ruthenium complexes can catalyze the oxidation of R$^1$–CHOH–R$^2$ to R$^1$–C(=O)–R$^2$ using a nitroxyl radical (*e.g.*, TEMPO, $n = 1$ for Cu, $n = 2$ for Ru) as the H$^{\bullet}$ abstracting reagent (iii) and O$_2$ as the terminal oxidant (iv). By a similar mechanism, a complex could catalyze radical reduction using a biologically relevant non-tertiary alcohol as the terminal reductant (v).

*aDepartment of Chemistry, Clemson University, Clemson, SC 29634, USA. E-mail: atennys@clemson.edu*

*bDepartment of Materials Science and Engineering, Clemson University, Clemson, SC 29634, USA*

*cCenter for Optical Materials Science and Engineering Technologies, Anderson, SC 29625, USA*

antioxidants or pro-oxidants will be determined by the nature of the terminal reductant.

A catalytic oxidation reaction important in synthetic chemistry is the aerobic oxidation of $R^1$–CHOH–$R^2$ to $R^1$–C(=O)–$R^2$ that does not cause any (1) over-oxidation to R–COOH or (2) undesired reactions at other functional groups.[19–23] One strategy employs a copper or ruthenium catalyst in conjunction with a nitroxyl radical, such as 2,2,6,6-tetramethylpiperidinyl-$N$-oxyl (TEMPO), to oxidize $R^1$–CHOH–$R^2$ to $R^1$–C(=O)–$R^2$ with concomitant formation of TEMPO–H (Scheme 1-iii). Subsequent regeneration of the TEMPO radical occurs with the oxidation of TEMPO–H by $O_2$, which functions as the terminal oxidant for this reaction (Scheme 1-iv). Because the TEMPO radical is reduced by $R^1$–CHOH–$R^2$ in the aerobic alcohol oxidation catalytic cycle, we hypothesized that the catalytic reduction of other radicals could also be achieved via the oxidation (*i.e.*, dehydrogenation) of non-tertiary alcohols (Scheme 1-v). Herein we report the validation of this hypothesis with an organoruthenium complex that catalyzes the reduction and inhibits the formation of radicals in buffered aqueous solutions via the oxidation of biologically-relevant non-tertiary alcohols. Given the successes of group 8 transfer hydrogenation catalysts as chemotherapeutics[24,25] in particular and the burgeoning scope of medicinal applications for transition metal-based catalytic systems[26–28] in general, we anticipate that the reduction of radicals via the Ru-catalyzed oxidation of alcohols will lead to new strategies for protecting against ROS *in vivo*.

## Results and discussion

### Approach and rationale

We recently reported a Ru complex supported by a chelating N-heterocyclic carbene–carboxylate ligand (**Ru1**, Scheme 2A) that catalyzed the hydrogenation of C=O, C=N and C=C bonds, in which the $H_2$ transferred was obtained from the oxidation of i-PrOH to acetone.[29] Based on this catalytic chemical reactivity observed with **Ru1** and previous reports of other Ru complexes with chelating carboxylate ligands exerting antioxidant effects in cells, which derived from irreversible stoichiometric reactions with nitric oxide,[30,31] we hypothesized that **Ru1** would function as a catalytic antioxidant, reducing radicals using non-tertiary alcohols as terminal reductants. Using methods previously reported by our group,[29,32] the N-heterocyclic carbene (NHC) ligand precursor [$1H_2$][Br] was treated with $Ag_2O$ to afford the Ag–NHC complex [Ag(1)]$_n$ (**2**). The NHC ligand was subsequently transferred to Ru via the reaction of **2** with [{RuCl($\eta^6$-cymene)}$_2$($\mu$-Cl)$_2$], which yielded the Ru–NHC complex [RuCl(1)($\eta^6$-cymene)] (**Ru1**).

As a radical substrate to probe antioxidant activity, 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonate) radical mono-anion (ABTS$^{•–}$, Scheme 2B) was selected on the basis of its large extinction coefficient ($\varepsilon$) at long wavelengths ($\varepsilon_{750} = 1.6 \times 10^4$ $M^{-1}$ $cm^{-1}$ in EtOH and $\varepsilon_{734} = 1.5 \times 10^4$ $M^{-1}$ $cm^{-1}$ in aqueous buffer),[33] its reversible one-electron reduction to ABTS$^{2–}$ ($E_{1/2} = 0.68$ V *vs.* NHE) falling within the range of potentials accessible in biological systems (−0.4 to +0.8 V *vs.* NHE),[34] and its stability in aerobic, protic media. The longer absorption wavelength and



**Scheme 2** (A) Synthesis of [$1H_2$][Br], **2** and **Ru1**. Reagents and conditions: (a) $Ag_2O$ (1.5 equiv.) or (b) [{RuCl($\eta^6$-cymene)}$_2$($\mu$-Cl)$_2$] (1 : 1 Ag/Ru), $CH_2Cl_2$, room temperature, 24 h. R = $p$-tolyl. (B) One-electron redox interconversion between ABTS$^{•–}$ and ABTS$^{2–}$ (NH$_4^+$ counterions omitted for clarity). (C) First and second one-electron oxidations of Trolox.

greater extinction coefficient for ABTS$^{•–}$ enables spectroscopic analysis of radical-degrading and -forming reactions (1) with less interference from other optically absorbing species present in biological systems and (2) at lower concentrations‡ more relevant to oxidative stress than would be possible with direct measurements of $O_2^{•–}$ ($\varepsilon_{250} = 1.9 \times 10^3$ $M^{-1}$ $cm^{-1}$) or $H_2O_2$ ($\varepsilon_{240} = 43.6$ $M^{-1}$ $cm^{-1}$).[35,36] Furthermore, the 1e$^-$ reduction potential for ABTS$^{•–}$ is lower than or comparable to the standard reduction potentials for several of the oxidizing species associated with oxidative stress in biological systems (*e.g.*, $E° = 1.78$ V for $H_2O_2$, 1.6 V for RO$^•$, 1.0 V for ROO$^•$, 0.92 V for Cys–S$^•$, 0.70 for $O_2$, *etc.*),[34] therefore ABTS$^{•–}$ is a reasonable substrate for approximating biologically-relevant oxidants.

As a non-catalytic antioxidant control, Trolox (Scheme 2C) was employed given its use as a benchmark in a variety of radical degradation and antioxidant studies.[37] Trolox can serve as a 1e$^-$ or 2e$^-$ reductant, whereby the first 1e$^-$ oxidation is accompanied by rapid H$^+$ loss to form a phenoxyl radical (TrO$^•$), which can then undergo a second 1e$^-$ oxidation to form a phenoxonium cation (TrO$^+$). However, in methanol (MeOH) or ethanol (EtOH) solutions, these processes converge into a single 2e$^-$ oxidation.[38] Subsequent hydrolysis of TrO$^+$ can then cleave the tertiary carbon–oxonium bond, which renders the 2e$^-$ oxidation of Trolox irreversible.

Because ROS and other oxidants can cause damage to critical biomolecules, inhibiting the formation of these oxidizing species in biological systems can potentially prevent the onset of harmful pathologies.[2] As a model system, we selected the oxidation of ABTS$^{2–}$ to ABTS$^{•–}$ by horseradish peroxidase (HRP) and $H_2O_2$ (*i.e.*, Scheme 1-ii).[39] However, before studying the ability of **Ru1** to inhibit ABTS$^{•–}$ formation, it was first necessary to explore the fundamental reactivity of **Ru1** with ABTS$^{•–}$ under controlled conditions and achieve the catalytic reduction of ABTS$^{•–}$ to ABTS$^{2–}$ in buffered aqueous solution.

## Catalytic radical reduction in EtOH

Addition of 5 μM **Ru1** (CH$_3$CN stock) to 50 μM ABTS$^{\bullet-}$ in EtOH caused a 100% decay in ABTS$^{\bullet-}$ concentration within 15 min (Fig. 1, red line), accompanied by the formation of 50 μM ABTS$^{2-}$ (Fig. S1†), indicating the 1 : 1 conversion of ABTS$^{\bullet-}$ to ABTS$^{2-}$ by **Ru1**. No ABTS$^{\bullet-}$ degradation occurred when CH$_3$CN alone was added (Fig. 1, dotted green line), indicating that **Ru1** was essential for the reduction of ABTS$^{\bullet-}$ to ABTS$^{2-}$ and that CH$_3$CN did not impact ABTS$^{\bullet-}$ stability. No ABTS$^{\bullet-}$ formation was observed in an aerobic solution containing 5 μM **Ru1** and 50 μM ABTS$^{2-}$, indicating that **Ru1** does not oxidize ABTS$^{2-}$ to ABTS$^{\bullet-}$ under these conditions. In contrast to **Ru1**, the addition of 5 μM Trolox caused a rapid (within mixing time) 22% decrease in ABTS$^{\bullet-}$ concentration (Fig. 1, blue line), which corresponded to the reduction of 10 μM ABTS$^{\bullet-}$ (2 equiv. *vs.* Trolox) and was consistent with the ability of Trolox to serve as a non-catalytic 2e$^-$ reductant in EtOH solution.[38]

To assess its catalytic potential and corresponding regeneration, the reactivity of **Ru1** with multiple sequential aliquots of excess ABTS$^{\bullet-}$ was examined. After the reduction of 50 μM ABTS$^{\bullet-}$ by 5 μM **Ru1** was complete (Fig. 2, red line), 2 additional 50 μM ABTS$^{\bullet-}$ aliquots were introduced§ and complete ABTS$^{\bullet-}$ reduction was observed in each instance, indicating that **Ru1** remained catalytically competent for the complete reduction of



**Fig. 1** Plot of relative [ABTS$^{\bullet-}$] *vs.* time in EtOH following the addition of **Ru1** (CH$_3$CN stock, red line), Trolox (CH$_3$CN stock, blue line), or CH$_3$CN alone (dotted green line). Conditions: [**Ru1**]$_0$ or [Trolox] = 5 μM, [ABTS$^{\bullet-}$]$_0$ = 50 μM, EtOH, 25 °C; [ABTS$^{\bullet-}$] determined using absorbance measured at 750 nm and $\varepsilon_{750} = 1.6 \times 10^4$ M$^{-1}$ cm$^{-1}$ (ref. 33).



**Fig. 2** Plot of relative [ABTS$^{\bullet-}$] *vs.* time which shows the reduction of ABTS$^{\bullet-}$ after adding **Ru1** (red line) followed by 2 additional 50 μM ABTS$^{\bullet-}$ aliquots (*) and Trolox (blue line) followed by 2 additional 10 μM ABTS$^{\bullet-}$ aliquots (*), then 5 μM **Ru1**. Conditions: [**Ru1**]$_0$ or [Trolox]$_0$ = 5 μM, [ABTS$^{\bullet-}$]$_0$ = 50 μM, EtOH, 25 °C; [ABTS$^{\bullet-}$] determined using absorbance measured at 750 nm and $\varepsilon_{750} = 1.6 \times 10^4$ M$^{-1}$ cm$^{-1}$ (ref. 33).

150 μM ABTS$^{\bullet-}$ (30 turnovers). Unlike **Ru1**, the addition of successive 10 μM aliquots§ of ABTS$^{\bullet-}$ following the initial reduction by 5 μM Trolox (Fig. 2, blue line) only caused the radical absorbance to increase by amounts equivalent to the concentration of ABTS$^{\bullet-}$ added, indicating that the antioxidant capacity of Trolox had been exhausted after the reduction of only 2 equiv. of ABTS$^{\bullet-}$. However, subsequent addition of 5 μM **Ru1** to the exhausted Trolox solution containing 70 μM ABTS$^{\bullet-}$ resulted in 100% radical reduction within 30 min.

Addition of 5 μM ascorbate (AscH$^-$) or 5 μM glutathione (GSH) to a solution of 50 μM ABTS$^{\bullet-}$ in EtOH caused the ABTS$^{\bullet-}$ concentration to decrease by 5% or 60% (Fig. S2 and S3†), values that were consistent with their ability to function as 1e$^-$ or 6e$^-$ reductants, respectively, under these experimental conditions.[40–42] Similar to the experiments with Trolox, subsequent addition of ABTS$^{\bullet-}$ only afforded increases in radical absorbance equal to the concentration of ABTS$^{\bullet-}$ added, which likewise indicated that the antioxidant capacity of AscH$^-$ and GSH had been exhausted. Quantitative radical reduction could nonetheless be achieved *via* addition of 5 μM **Ru1** to the exhausted AscH$^-$ or GSH solutions that contained excess ABTS$^{\bullet-}$. Collectively, these data demonstrate that **Ru1** can catalytically reduce ABTS$^{\bullet-}$ and, because it is regenerated after each reaction cycle, that a catalytic antioxidant can offer significantly greater protection than traditional stoichiometric antioxidants, such as Trolox, AscH$^-$ and GSH.

Although ABTS$^{\bullet-}$ degradation has been previously observed with other Ru complexes,[43–45] **Ru1** is the first to demonstrate catalytic ABTS$^{\bullet-}$ reduction. It is important to note that the previous studies measured percentage of ABTS$^{\bullet-}$ degradation with respect to Ru complex concentration, for the purpose of determining the dose dependence of radical degradation. However, the reported absorbance *vs.* time plots displayed significantly slower ABTS$^{\bullet-}$ degradation for the Ru complexes compared to Trolox (much like **Ru1** *vs.* Trolox, Fig. 1) and 100% ABTS$^{\bullet-}$ degradation at multiple Ru concentrations (demonstrating dose independence). Thus, it is possible that a previously reported Ru complex may have degraded ABTS$^{\bullet-}$ catalytically, but its significantly slower reactivity compared to Trolox created the appearance that the percent of ABTS$^{\bullet-}$ degraded was dependent on Ru complex concentration and led to the conclusion that the observed radical degradation was non-catalytic.

## Catalytic radical reduction in aqueous buffer

As a catalyst for the 1e$^-$ reduction of ABTS$^{\bullet-}$ to ABTS$^{2-}$, **Ru1** itself cannot serve as the terminal reductant for this reaction, a role most likely played by the EtOH solvent for the experiments displayed in Fig. 1. To test this hypothesis and identify the chemical features required for terminal reductant function, it was first necessary to determine experimental conditions under which no ABTS$^{\bullet-}$ degradation occurred in the presence of **Ru1** alone. Phosphate-buffered saline (PBS, pH 7.4) was selected as a suitable reaction medium because neither the solvent (H$_2$O) nor the buffer components (Na$_2$HPO$_4$, KH$_2$PO$_4$, NaCl, KCl) would undergo oxidation to supply the electrons necessary

**Fig. 3** Plot of relative [ABTS$^{\bullet-}$] vs. time which shows the catalytic reduction of ABTS$^{\bullet-}$ by **Ru1** in PBS. By itself, ABTS$^{\bullet-}$ was stable in PBS (i, green line). Addition of **Ru1** did not cause ABTS$^{\bullet-}$ reduction (ii, red line). Subsequent addition of EtOH caused the absorbance to decrease (iii, blue line), which indicated that EtOH functioned as a terminal reductant. Conditions: [**Ru1**]$_0$ = 5 μM, [ABTS$^{\bullet-}$]$_0$ = 50 μM, [EtOH]$_0$ = 50 mM, PBS (pH 7.4), 25 °C; [ABTS$^{\bullet-}$] determined using absorbance measured at 734 nm and $\varepsilon_{734} = 1.5 \times 10^4$ M$^{-1}$ cm$^{-1}$ (ref. 33).

for the reduction of ABTS$^{\bullet-}$ (i.e., Fig. 3-i). No degradation of ABTS$^{\bullet-}$ in PBS was observed after treatment with 5 μM **Ru1** (Fig. 3-ii), indicating this solution lacked a suitable terminal reductant. Subsequent addition of 50 mM EtOH to this PBS solution containing 5 μM **Ru1** and 50 μM ABTS$^{\bullet-}$ caused the ABTS$^{\bullet-}$ concentration to decrease (Fig. 3-iii), evidence that the electrons needed for the ABTS$^{\bullet-}$ reduction observed in Fig. 1 were ultimately supplied by the EtOH solvent.

If the hypothesis that the oxidation of R$_1$–CHOH–R$_2$ to R$_1$–C(=O)–R$_2$ provides the electrons necessary for the reduction of ABTS$^{\bullet-}$ to ABTS$^{2-}$ is correct (i.e., Scheme 1-v), then both the O–H and C–H groups in a –CHOH– moiety will be essential for terminal reductant function. To test this hypothesis, PBS solutions containing 5 μM **Ru1** and 50 μM ABTS$^{\bullet-}$ were treated with 50 mM MeOH, i-PrOH, t-BuOH, ethylene glycol (EG) or 1,2-dimethoxyethane (DME) and the ABTS$^{\bullet-}$ concentration was measured. With MeOH, i-PrOH and EG, the ABTS$^{\bullet-}$ concentration began to decrease immediately following addition of the alcohol, indicating that these alcohols could serve as terminal reductants (Fig. S4–S6†). In contrast, no ABTS$^{\bullet-}$ reduction was

observed with DME or t-BuOH (e.g., Fig. 4-ii). However, when the addition of 50 mM t-BuOH was followed by 50 mM EtOH, ABTS$^{\bullet-}$ reduction did occur (Fig. 4-iii), revealing that the lack of reactivity with t-BuOH was not due to catalyst deactivation but rather the inability of t-BuOH to serve as a terminal reductant. Collectively, these results show that the C–H and O–H groups of a –CHOH– moiety are both essential for terminal reductant function, which is consistent with the hypothesis that oxidation of R$_1$–CHOH–R$_2$ to R$_1$–C(=O)–R$_2$ provides the reducing equivalents necessary to convert ABTS$^{\bullet-}$ to ABTS$^{2-}$. Replacing either the C–H group with C–Me or the O–H group with O–Me precludes this oxidation and thus the ability to function as a terminal reductant, which is supported by the lack of ABTS$^{\bullet-}$ reduction observed with t-BuOH and DME.

### Biologically-relevant terminal reductants

A wide variety of biomolecules comprise –CHOH– groups, therefore we hypothesized that sugars, amino acids and citric acid cycle metabolites could serve as suitable terminal reductants in **Ru1**-catalyzed ABTS$^{\bullet-}$ reduction. To test this hypothesis, PBS solutions containing 5 μM **Ru1** and 50 μM ABTS$^{\bullet-}$ were treated with 50 mM serine, threonine, glucose, arabinose, malic acid or lactic acid. Reduction of ABTS$^{\bullet-}$ was markedly slower following the addition of the amino acids compared to the sugars, consistent with the greater number of CH–OH groups per molecule in the latter (Fig. 5). No significant differences in reactivity were observed between serine and threonine or between glucose and arabinose.

Malic acid and lactic acid are metabolites of the citric acid cycle and each comprises a –CHOH– group. However, no ABTS$^{\bullet-}$ reduction occurred following the addition of 50 mM malic acid or lactic acid to 5 μM **Ru1** and 50 μM ABTS$^{\bullet-}$ in PBS (Fig. 6). Malate and lactate will be the predominant species in pH 7.4 PBS, and these carboxylate anions can function as chelating bidentate ligands, which could potentially disrupt the catalytic activity of **Ru1**. To prevent catalyst deactivation, the methyl esters of these substrates were used. Addition of 50 mM methyl lactate (Me-lactate) or dimethyl malate (Me$_2$-malate) to PBS solutions containing 5 μM **Ru1** and 50 μM ABTS$^{\bullet-}$ caused the ABTS$^{\bullet-}$ concentration to decrease rapidly. None of the biologically-relevant alcohols afforded ABTS$^{\bullet-}$ reduction in the



**Fig. 4** Plot of relative [ABTS$^{\bullet-}$] vs. time which shows the catalyst is not deactivated by t-BuOH. In a PBS solution containing only **Ru1**, ABTS$^{\bullet-}$ was stable (i, red line). Addition of t-BuOH did not cause any ABTS$^{\bullet-}$ reduction (ii, orange line). Subsequent addition of EtOH resulted in ABTS$^{\bullet-}$ degradation (iii, blue line), indicating that the lack of reactivity with t-BuOH was not due to catalyst deactivation. Conditions [**Ru1**]$_0$ = 5 μM, [ABTS$^{\bullet-}$]$_0$ = 50 μM, [t-BuOH]$_0$ = 50 mM, [EtOH]$_0$ = 50 mM, PBS (pH 7.4), 25 °C; [ABTS$^{\bullet-}$] determined using absorbance measured at 734 nm and $\varepsilon_{734} = 1.5 \times 10^4$ M$^{-1}$ cm$^{-1}$ (ref. 33).



**Fig. 5** Plot of relative [ABTS$^{\bullet-}$] vs. time following the addition of amino acid or sugar ($t = 0$) to PBS solutions containing ABTS$^{\bullet-}$ and **Ru1**. Conditions: [**Ru1**]$_0$ = 5 μM, [ABTS$^{\bullet-}$]$_0$ = 50 μM, [ROH]$_0$ = 50 mM, PBS (pH 7.4), 25 °C; [ABTS$^{\bullet-}$] determined using absorbance measured at 734 nm and $\varepsilon_{734} = 1.5 \times 10^4$ M$^{-1}$ cm$^{-1}$ (ref. 33).

**Fig. 6** Plot of relative $[ABTS^{\bullet-}]$ vs. time following the addition of lactate, malate or their methyl esters ($t = 0$) to PBS solutions containing $ABTS^{\bullet-}$ and **Ru1**. Conditions: $[\mathbf{Ru1}]_0 = 5\ \mu M$, $[ABTS^{\bullet-}]_0 = 50\ \mu M$, $[ROH]_0 = 50\ mM$, PBS (pH 7.4), 25 °C; $[ABTS^{\bullet-}]$ determined using absorbance measured at 734 nm and $\varepsilon_{734} = 1.5 \times 10^4\ M^{-1}\ cm^{-1}$ (ref. 33).

absence of **Ru1**, and no oxidation of $ABTS^{2-}$ to $ABTS^{\bullet-}$ by **Ru1** was observed under any experimental conditions in PBS.

### Inhibition of oxidative radical formation

Having obtained unambiguous evidence that **Ru1** catalyzes $ABTS^{\bullet-}$ reduction using biologically-relevant alcohols as terminal reductants, we next sought to demonstrate that **Ru1** could also inhibit radical formation. As the model system, we utilized the *in situ* oxidation of $ABTS^{2-}$ to $ABTS^{\bullet-}$ by horseradish peroxidase (HRP) and $H_2O_2$ (*i.e.*, Scheme 1-ii).[39] Addition of 10 μM $H_2O_2$ to a PBS solution of 10 nM HRP, 20 μM $ABTS^{2-}$, 5 μM **Ru1**, and 50 mM EtOH caused the $ABTS^{\bullet-}$ concentration to increase immediately. The $ABTS^{\bullet-}$ concentration peaked at 1.0 μM after 2.3 min, which then gradually declined and complete $ABTS^{\bullet-}$ reduction was observed 13 min after the peak (Fig. 7A, red line). No $ABTS^{\bullet-}$ formation occurred when 10 μM $H_2O_2$ was added to 5 μM **Ru1** and 20 μM $ABTS^{2-}$ in PBS, indicating that **Ru1** did not cause any pro-oxidant reactions. Because **Ru1** and Trolox were added as 30 μL aliquots from 5.0 mM stock solutions in $CH_3CN$, 10 μM $H_2O_2$ was added to a PBS solution containing 10 nM HRP, 20 μM $ABTS^{2-}$ and 0.19 M $CH_3CN$ to control for the influence of this solvent. The radical absorbance immediately began to increase and reached a maximum of 17.9 μM after 50 min (Fig. 7A, dotted green line and Fig. S7†). In contrast, the addition

of 10 μM $H_2O_2$ to a PBS solution of 5 μM Trolox, 10 nM HRP and 20 μM $ABTS^{2-}$ resulted in no change in $ABTS^{\bullet-}$ concentration for the first 7.6 min, demonstrating that Trolox completely halted $ABTS^{\bullet-}$ formation (Fig. 7A, blue line). After 7.6 min, however, the $ABTS^{\bullet-}$ concentration began to increase and reached a maximum of 9.3 μM at 12 min after the onset of $ABTS^{\bullet-}$ formation. Notably, the maximum $[ABTS^{\bullet-}]$ observed in the presence of Trolox was 8.6 μM lower than the control, which was consistent with the ability of Trolox to function as a $2e^-$ reductant (*cf.*, the 22% decrease observed with Trolox in Fig. 1A). For the control and Trolox experiments, the decline in $ABTS^{\bullet-}$ concentration after peaking was consistent with normal $ABTS^{\bullet-}$ thermal decay.

To determine if **Ru1** remained catalytically competent after the complete reduction of $ABTS^{\bullet-}$ formed by 10 nM HRP and 10 μM $H_2O_2$, two additional 10 μM aliquots of $H_2O_2$ were introduced (Fig. 7B, red line). Impressively, the concentration of $ABTS^{\bullet-}$ never exceeded 0.4 μM and decreased back to zero in less than 16 min after the introduction of the second and third $H_2O_2$ aliquots. In contrast, addition of the second 10 μM $H_2O_2$ aliquot to the Trolox experiment caused the $ABTS^{\bullet-}$ concentration to gradually increase by 7.9 μM over the course of 38 min (Fig. 7B, blue line), effectively resulting in complete oxidation of $ABTS^{2-}$ to $ABTS^{\bullet-}$ (96% of the 17.9 μM observed for control). It was therefore unsurprising that the third 10 μM $H_2O_2$ aliquot produced no change in radical absorbance. Subsequent addition of 50 mM EtOH and 5 μM **Ru1** caused the $ABTS^{\bullet-}$ concentration to decrease rapidly, affording quantitative $ABTS^{\bullet-}$ reduction in less than 30 min.

To confirm that the results obtained with **Ru1** arose from its ability to catalyze $ABTS^{\bullet-}$ reduction, rather than inhibiting HRP or another chemical reaction, two 10 μM aliquots of chemically synthesized $ABTS^{\bullet-}$ were introduced after the $ABTS^{\bullet-}$ concentration had decreased to zero following the initial addition of 10 μM $H_2O_2$ (Fig. 7C, red line). The first and second $ABTS^{\bullet-}$ aliquots produced immediate increases in $ABTS^{\bullet-}$ concentration corresponding to 6.3 and 6.7 μM, respectively, followed by rapid decreases in radical absorbance that resulted in quantitative radical reduction within 75 s of aliquot addition. With the Trolox experiment, however, the first and second $ABTS^{\bullet-}$ aliquots caused $[ABTS^{\bullet-}]$ to increase by 9.9 and 9.7 μM, respectively, with



**Fig. 7** (A) Plot of relative $[ABTS^{\bullet-}]$ vs. time which shows the *in situ* oxidation of $ABTS^{2-}$ to $ABTS^{\bullet-}$ via HRP and $H_2O_2$ in the presence of **Ru1** and EtOH (red line), Trolox (blue line) or 0.19 M $CH_3CN$ as a control (dotted green line). Plot of relative $[ABTS^{\bullet-}]$ vs. time which shows the (B) $ABTS^{\bullet-}$ formation by HRP in the presence of **Ru1** and EtOH (red line) or Trolox (blue line) followed by two additional aliquots of 10 μM $H_2O_2$ (#) or (C) two 10 μM aliquots of chemically synthesized $ABTS^{\bullet-}$ (*). For the Trolox experiments shown in (B) or (C), 50 mM EtOH and 5 μM **Ru1** were added after the final aliquot of $H_2O_2$ or $ABTS^{\bullet-}$, respectively. Conditions: $[HRP]_0 = 10\ nM$ $[\mathbf{Ru1}]_0$ or $[Trolox]_0 = 5\ \mu M$, $[H_2O_2]_0 = 10\ \mu M$, $[ABTS^{2-}]_0 = 20\ \mu M$, $[EtOH]_0 = 50\ mM$, PBS (pH 7.4) at 25 °C; $[ABTS^{\bullet-}]$ determined using absorbance measured at 734 nm and $\varepsilon_{734} = 1.5 \times 10^4\ M^{-1}\ cm^{-1}$ (ref. 33).

no observable changes in radical absorbance other than thermal decay (Fig. 7C, blue line). Addition of 50 mM EtOH and 5 μM **Ru1** after the second ABTS$^{•-}$ aliquot afforded complete ABTS$^{•-}$ reduction within 30 min, similar to the experiment with multiple $H_2O_2$ aliquots. Both AscH$^-$ and GSH inhibited the HRP-induced oxidation of ABTS$^{2-}$, albeit for shorter periods of time and less effectively than Trolox. The introduction of additional $H_2O_2$ (Fig. S8 and S9†) or ABTS$^{•-}$ aliquots (Fig. S10 and S11†) only afforded increases in ABTS$^{•-}$ concentration that mirrored the behaviors observed for Trolox (*i.e.*, Fig. 7B and C). Subsequent addition of 50 mM EtOH and 5 μM **Ru1** to the AscH$^-$ and GSH solutions containing excess ABTS$^{•-}$ produced quantitative radical reduction, consistent with the Trolox experiments.

## Conclusions

An organoruthenium complex (**Ru1**) that was previously reported to catalyze the hydrogenation of unsaturated organic substrates, using the oxidation of i-PrOH to acetone to supply the needed $H_2$, has now been shown to also catalyze the reduction of ABTS$^{•-}$ to ABTS$^{2-}$ in buffered aqueous solution. By itself, **Ru1** was unreactive towards ABTS$^{•-}$ and the presence of a non-tertiary alcohol was essential for ABTS$^{•-}$ reduction to occur. Replacing either the C–H or O–H group in a –CHOH– moiety with C–Me or O–Me, respectively, resulted in the loss of ABTS$^{•-}$ reducing ability. Given the previously reported transfer hydrogenation activity of **Ru1** and the fact that **Ru1**-catalyzed ABTS$^{•-}$ reduction required a reactant comprising a –CHOH– moiety, we deduced that the reducing equivalents necessary for the 1e$^-$ reduction of ABTS$^{•-}$ to ABTS$^{2-}$ were supplied by the oxidation of $R_1$–CHOH–$R_2$ to $R_1$–C(=O)–$R_2$. Consistent with this deduction, a diverse array of biologically-relevant non-tertiary alcohols, including amino acids, sugars and citric acid cycle metabolites, were found to be suitable terminal reductants for the reduction of ABTS$^{•-}$ catalyzed by **Ru1**. Furthermore, in conjunction with an alcohol terminal reductant, **Ru1** was able to inhibit the oxidation of ABTS$^{2-}$ to ABTS$^{•-}$ by $H_2O_2$ and horseradish peroxidase. In contrast, non-catalytic antioxidants (Trolox, ascorbate, glutathione), only offered limited protection that, once exhausted, had no impact on ABTS$^{•-}$ formation or stability. Impressively, no ABTS$^{•-}$ formation or other pro-oxidant effects by **Ru1** were observed under any experimental conditions. The mechanism for the catalytic reduction of ABTS$^{•-}$ by **Ru1** and non-tertiary alcohols, along with the biological applications, will be detailed in subsequent reports.

## Acknowledgements

## Notes and references

‡ In PBS, an ABTS$^{•-}$ concentration of 6.7 μM would give rise to an absorbance value of 0.1. Achieving a similar value with $O_2^{•-}$ or $H_2O_2$ would require a concentration of 53 μM or 2.29 mM, respectively.

§ The concentration of the successive ABTS$^{•-}$ aliquots was selected based on the concentration of the initial 50 μM ABTS$^{•-}$ that was degraded by the antioxidant. Because **Ru1** degraded all of the initial 50 μM ABTS$^{•-}$ and Trolox only degraded 10 μM, the concentration of the multiple sequential aliquots added was 50 μM with **Ru1** and 10 μM with Trolox.

1 M. P. Murphy, *Biochem. J.*, 2009, **417**, 1–13.
2 M. Valko, D. Leibfritz, J. Moncol, M. T. D. Cronin, M. Mazur and J. Telser, *Int. J. Biochem. Cell Biol.*, 2007, **39**, 44–84.
3 M. S. Cooke, M. D. Evans, M. Dizdaroglu and J. Lunec, *FASEB J.*, 2003, **17**, 1195–1214.
4 W. Maret, *Antioxid. Redox Signaling*, 2006, **8**, 1419–1441.
5 R. Stocker and J. F. Keaney Jr, *Physiol. Rev.*, 2004, **84**, 1381–1478.
6 T. Fukai and M. Ushio-Fukai, *Antioxid. Redox Signaling*, 2011, **15**, 1583–1606.
7 S. Miriyala, I. Spasojevic, A. Tovmasyan, D. Salvemini, Z. Vujaskovic, D. S. Clair and I. Batinic-Haberle, *Biochim. Biophys. Acta*, 2012, **1822**, 794–814.
8 I. Batinic-Haberle, A. Tovmasyan, E. R. H. Roberts, Z. Vujaskovic, K. W. Leong and I. Spasojevic, *Antioxid. Redox Signaling*, 2014, **20**, 2372–2415.
9 S. D. Amaral and B. P. Espósito, *Biometals*, 2008, **21**, 425–432.
10 M. K. Evans, A. Tovmasyan, I. Batinic-Haberle and G. R. Devi, *Free Radical Biol. Med.*, 2014, **68**, 302–314.
11 P. Chelikani, I. Fita and P. C. Loewen, *Cell. Mol. Life Sci.*, 2004, **61**, 192–208.
12 H.-P. Hersleth, U. Ryde, P. Rydberg, C. H. Görbitz and K. K. Andersson, *J. Inorg. Biochem.*, 2006, **100**, 460–476.
13 H. N. Kirkman and G. F. Gaetani, *Trends Biochem. Sci.*, 2007, **32**, 44–50.
14 J. Vlasits, C. Jakopitsch, M. Bernroitner, M. Zamocky, P. G. Furtmüller and C. Obinger, *Arch. Biochem. Biophys.*, 2010, **500**, 74–81.
15 R. Kubota, S. Imamura, T. Shimizu, S. Asayama and H. Kawakami, *ACS Med. Chem. Lett.*, 2014, **5**, 639–643.
16 M. A. Sharpe, R. Olloson, V. C. Stewart and J. B. Clark, *Biochem. J.*, 2002, **366**, 97–107.
17 M. Itoh, K.-i. Motoda, K. Shindo, T. Kamiusuki, H. Sakiyama, N. Matsumoto and H. Ōkawa, *J. Chem. Soc., Dalton Trans.*, 1995, 3635–3641.
18 Y. Naruta and K. Maruyama, *J. Am. Chem. Soc.*, 1991, **113**, 3595–3596.
19 R. A. Sheldon, *Catal. Today*, 2015, **247**, 4–13.
20 B. L. Ryland and S. S. Stahl, *Angew. Chem., Int. Ed.*, 2014, **53**, 8824–8838.
21 Y. Seki, K. Oisaki and M. Kanai, *Tetrahedron Lett.*, 2014, **55**, 3738–3746.
22 C. Parmeggiani and F. Cardona, *Green Chem.*, 2012, **14**, 547–564.
23 M. J. Schultz and M. S. Sigman, *Tetrahedron*, 2006, **62**, 8227–8241.
24 J. J. Soldevila-Barreda, I. Romero-Canelón, A. Habtemariam and P. J. Sadler, *Nat. Commun.*, 2015, **6**, 6582.
25 Y. Fu, M. J. Romero, A. Habtemariam, M. E. Snowden, L. Song, G. J. Clarkson, B. Qamar, A. M. Pizarro, P. R. Unwin and P. J. Sadler, *Chem. Sci.*, 2012, **3**, 2485–2494.

26 J. J. Soldevila-Barreda and P. J. Sadler, *Curr. Opin. Chem. Biol.*, 2015, **25**, 172–183.

27 P. K. Sasmal, C. N. Streu and E. Meggers, *Chem. Commun.*, 2013, **49**, 1581–1587.

28 G. Gasser and N. Metzler-Nolte, *Curr. Opin. Chem. Biol.*, 2012, **16**, 84–91.

29 A. Mangalum, C. D. McMillen and A. G. Tennyson, *Inorg. Chim. Acta*, 2015, **426**, 29–38.

30 S. P. Fricker, E. Slade, N. A. Powell, O. J. Vaughan, G. R. Henderson, B. A. Murrer, I. L. Megson, S. K. Bisland and F. W. Flitney, *Br. J. Pharmacol.*, 1997, **122**, 1441–1449.

31 B. R. Cameron, M. C. Darkes, H. Yee, M. Olsen, S. P. Fricker, R. T. Skerlj, G. J. Bridger, N. A. Davies, M. T. Wilson, D. J. Rose and J. Zubieta, *Inorg. Chem.*, 2003, **42**, 1868–1876.

32 A. Mangalum, Y. Htet, D. A. Roe, C. D. McMillen and A. G. Tennyson, *Inorg. Chim. Acta*, 2015, **435**, 320–326.

33 R. Re, N. Pellegrini, A. Proteggente, A. Pannala, M. Yang and C. Rice-Evans, *Free Radical Biol. Med.*, 1999, **26**, 1231–1237.

34 U. Jungwirth, C. R. Kowol, B. K. Keppler, C. G. Hartinger, W. Berger and P. Heffeter, *Antioxid. Redox Signaling*, 2011, **15**, 1085–1127.

35 B. H. J. Bielski and A. O. Allen, *J. Phys. Chem.*, 1977, **81**, 1048–1050.

36 K. Yusa and K. Shikama, *Biochemistry*, 1987, **26**, 6684–6688.

37 D. Huang, B. Ou and R. L. Prior, *J. Agric. Food Chem.*, 2005, **53**, 1841–1856.

38 M. Karbarz and J. Malyszko, *Electroanalysis*, 2008, **20**, 1884–1890.

39 L. Pitulice, I. Pastor, E. Vilaseca, S. Madurga, A. Isvoran, M. Cascante and F. Mas, *Biocatal. Biotransform.*, 2013, **2**, 1–5.

40 C. Creutz, *Inorg. Chem.*, 1981, **20**, 4449–4452.

41 J. M. Pullar, M. C. M. Vissers and C. C. Winterbourn, *J. Biol. Chem.*, 2001, **276**, 22120–22125.

42 S. Enami, M. R. Hoffmann and A. J. Colussi, *Chem. Res. Toxicol.*, 2009, **22**, 35–40.

43 P. Sathyadevi, P. Krishnamoorthy, N. S. P. Bhuvanesh, P. Kalaiselvi, V. V. Padma and N. Dharmaraj, *Eur. J. Med. Chem.*, 2012, **55**, 420–431.

44 Y. Liu, X. Zhang, R. Zhang, T. Chen, Y.-S. Wong, J. Liu and W.-J. Zheng, *Eur. J. Inorg. Chem.*, 2011, 1974–1980.

45 J. M. Alfaro, A. Prades, M. del Carmen Ramos, E. Peris, J. Ripoll-Gómez, M. Poyatos and J. S. Burgos, *Zebrafish*, 2010, **7**, 13–21.